Possible role of imatinib in clinical pulmonary veno-occlusive disease

70Citations
Citations of this article
42Readers
Mendeley users who have this article in their library.

Abstract

The platelet-derived growth factor receptor inhibitor imatinib has demonstrated clinical and haemodynamical improvement in both animal models of pulmonary hypertension (PH) and patients with PH. It has been suggested that anti-proliferative effects on pulmonary vascular smooth muscle cells are responsible for these beneficial effects. The current study describes a patient with pulmonary arterial hypertension associated with a suspected pulmonary veno-occlusive disease. Treatment with imatinib resulted in rapid clinical improvement and decrease of ground-glass opacities and lobular septal thickening on high-resolution computed tomography. Based on these findings and on in vitro effects of imatinib on permeability of the endothelium, the authors hypothesise that the rapid clinical outcome is partly due to effects of imatinib on vascular integrity. Copyright©ERS Journals Ltd 2008.

Cite

CITATION STYLE

APA

Overbeek, M. J., Van Nieuw Amerongen, G. P., Boonstra, A., Smit, E. F., & Vonk-Noordegraaf, A. (2008). Possible role of imatinib in clinical pulmonary veno-occlusive disease. European Respiratory Journal, 32(1), 232–235. https://doi.org/10.1183/09031936.00054407

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free